GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression

Neoplasia

Volumn 12, Issue 11, 2010, Pages 856-865

  Belaguli, Narasimhaswamy S ^a   Aftab, Muhammad ^a   Rigi, Mohammed ^a   Zhang, Mao ^a   Albo, Daniel ^a   Berger, David H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR SP1; UROKINASE;

ARTICLE; CANCER CELL; CELL INVASION; CELL NUCLEUS; COLON CANCER; COLON POLYP; CONTROLLED STUDY; CYTOPLASM; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECTUM POLYP; UPREGULATION;

EID: 78449260187     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10224     Document Type: Article

References (58)

1. Molkentin JD (2000). The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 275, 38949-38952.
2. Divine JK, Staloch LJ, Haveri H, Jacobsen CM, Wilson DB, Heikinheimo M, and Simon TC (2004). GATA-4, GATA-5, and GATA-6 activate the rat liver fatty acid binding protein gene in concert with HNF-1α. Am J Physiol Gastrointest Liver Physiol 287, G1086-G1099.
3. Fang R, Olds LC, and Sibley E (2006). Spatio-temporal patterns of intestinespecific transcription factor expression during postnatal mouse gut development. Gene Expr Patterns 6, 426-432.
4. Belaguli NS, Zhang M, Rigi M, Aftab M, and Berger DH (2007). Cooperation between GATA4 and TGF-β signaling regulates intestinal epithelial gene expression. Am J Physiol Gastrointest Liver Physiol 292, G1520-G1533.
5. Boudreau F, Rings EH, van Wering HM, Kim RK, Swain GP, Krasinski SD, Moffett J, Grand RJ, Suh ER, and Traber PG (2002). Hepatocyte nuclear factor-1α, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription. Implication for the developmental regulation of the sucrase-isomaltase gene. J Biol Chem 277, 31909-31917.
6. Fluck CE and Miller WL (2004). GATA-4 and GATA-6 modulate tissue-specific transcription of the human gene for P450c17 by direct interaction with Sp1. Mol Endocrinol 18, 1144-1157.
7. Zhou B, Francis TA, Yang H, Tseng W, Zhong Q, Frenkel B, Morrisey EE, Ann DK, Minoo P, Crandall ED, et al. (2008). GATA-6 mediates transcriptional activation of aquaporin-5 through interactions with Sp1. Am J Physiol Cell Physiol 295, C1141-C1150.
8. Agnihotri S, Wolf A, Picard D, Hawkins C, and Guha A (2009). GATA4 is a regulator of astrocyte cell proliferation and apoptosis in the human and murine central nervous system. Oncogene 28, 3033-3046.
9. Capo-Chichi CD, Roland IH, Vanderveer L, Bao R, Yamagata T, Hirai H, Cohen C, Hamilton TC, Godwin AK, and Xu XX (2003). Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Res 63, 4967-4977.
10. Kamnasaran D, Qian B, Hawkins C, Stanford WL, and Guha A (2007). GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model. Proc Natl Acad Sci USA 104, 8053-8058.
11. Kobayashi S, Lackey T, Huang Y, Bisping E, Pu WT, Boxer LM, and Liang Q (2006). Transcription factor gata4 regulates cardiac BCL2 gene expression in vitro and in vivo. FASEB J 20, 800-802.
12. Kwei KA, Bashyam MD, Kao J, Ratheesh R, Reddy EC, Kim YH, Montgomery K, Giacomini CP, Choi YL, Chatterjee S, et al. (2008). Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet 4, e1000081.
13. Perlman H, Suzuki E, Simonson M, Smith RC, and Walsh K (1998). GATA-6 induces p21(Cip1) expression andG1 cell cycle arrest. J BiolChem 273, 13713-13718.
14. Rojas A, Kong SW, Agarwal P, Gilliss B, Pu WT, and Black BL (2008). GATA4 is a direct transcriptional activator of Cyclin D2 and Cdk4 and is required for cardiomyocyte proliferation in anterior heart field-derived myocardium. Mol Cell Biol 28, 5420-5431.
15. Vuorenoja S, Rivero-Muller A, Kiiveri S, Bielinska M, Heikinheimo M, Wilson DB, Huhtaniemi IT, and Rahman NA (2007). Adrenocortical tumorigenesis, luteinizing hormone receptor and transcription factors GATA-4 and GATA-6. Mol Cell Endocrinol 269, 38-45.
16. Miller CT, Moy JR, Lin L, Schipper M, Normolle D, Brenner DE, Iannettoni MD, Orringer MB, and Beer DG (2003). Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res 9, 4819-4825.
17. Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart J, Smith KD, Mezhir JJ, Weichselbaum RR, et al. (2005). Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res 65, 3146-3154.
18. Fu B, Luo M, Lakkur S, Lucito R, and Iacobuzio-Donahue CA (2008). Frequent genomic copy number gain and overexpression ofGATA-6 in pancreatic carcinoma. Cancer Biol Ther 7, 1593-1601.
19. Steeg PS (2006). Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12, 895-904.
20. Choong PF and Nadesapillai AP (2003). Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 415, S46-S58.
21. Iiizumi M, Liu W, Pai SK, Furuta E, and Watabe K (2008). Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta 1786, 87-104.
22. Crippa MP (2007). Urokinase-type plasminogen activator. Int J Biochem Cell Biol 39, 690-694.
23. Shiou SR, Datta PK, Dhawan P, Law BK, Yingling JM, Dixon DA, and Beauchamp RD(2006). Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-β. J Biol Chem 281, 33971-33981.
24. Verde P, Boast S, Franze A, Robbiati F, and Blasi F (1988). An upstream enhancer and a negative element in the 5′ flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res 16, 10699-10716.
25. Nerlov C, Rorth P, Blasi F, and Johnsen M(1991). Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 6, 1583-1592.
26. Nerlov C, De CD, Pergola F, Caracciolo A, Blasi F, Johnsen M, and Verde P (1992). A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J 11, 4573-4582.
27. Ibanez-Tallon I, Ferrai C, Longobardi E, Facetti I, Blasi F, and Crippa MP (2002). Binding of Sp1 to the proximal promoter links constitutive expression of the human uPA gene and invasive potential of PC3 cells. Blood 100, 3325-3332.
28. Kojima S, Hayashi S, Shimokado K, Suzuki Y, Shimada J, Crippa MP, and Friedman SL (2000). Transcriptional activation of urokinase by the Kruppel-like factor Zf 9/COPEB activates latent TGF-β1 in vascular endothelial cells. Blood 95, 1309-1316.
29. Suzuki Y, Shimada J, Shudo K, Matsumura M, Crippa MP, and Kojima S (1999). Physical interaction between retinoic acid receptor and Sp1: mechanism for induction of urokinase by retinoic acid. Blood 93, 4264-4276.
30. Kopf E and Miskin R (2005). A RUNX/AML-binding motif residing in a novel 13-bp DNA palindrome may determine the expression of the proximal promoter of the human uPA gene. J Thromb Haemost 3, 2057-2064.
31. Sokabe T, Yamamoto K, Ohura N, Nakatsuka H, Qin K, Obi S, Kamiya A, and Ando J (2004). Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 287, H2027-H2034.
32. Chen B, Yates E, Huang Y, Kogut P, Ma L, Turner JR, Tao Y, Camoretti-Mercado B, Lang D, Svensson EC, et al. (2009). Alternative promoter and GATA5 transcripts in mouse. Am J Physiol Gastrointest Liver Physiol 297, G1214-G1222.
33. Hellebrekers DM, Lentjes MH, van den Bosch SM, Melotte V, Wouters KA, Daenen KL, Smits KM, Akiyama Y, Yuasa Y, Sanduleanu S, et al. (2009). GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res 15, 3990-3997.
34. Shureiqi I, Zuo X, Broaddus R, Wu Y, Guan B, Morris JS, and Lippman SM (2007). The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J 21, 743-753.
35. Haveri H, Westerholm-Ormio M, Lindfors K, Maki M, Savilahti E, Andersson LC, and Heikinheimo M (2008). Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC Gastroenterol 8, 9.
36. Charron F, Tsimiklis G, Arcand M, Robitaille L, Liang Q, Molkentin JD, Meloche S, and Nemer M (2001). Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev 15, 2702-2719.
37. Fletcher G, Jones GE, Patient R, and Snape A (2006). A role for GATA factors in Xenopus gastrulation movements. Mech Dev 123, 730-745.
38. Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell TG, O'Donoghue DP, and Sheahan K (1997). Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 3, 1837-1840.
39. Hafez MM, Infante D, Winawer S, and Friedman E (1990). Transforming growth factor β1 acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation. Cell Growth Differ 1, 617-626.
40. Hafez MM, Hsu S, Yan Z, Winawer S, and Friedman E (1992). Two roles for transforming growth factor β1 in colon enterocytic cell differentiation. Cell Growth Differ 3, 753-762.
41. Morikawa K, Walker SM, Jessup JM, and Fidler IJ (1988). In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 48, 1943-1948.
42. Pakneshan P, Szyf M, and Rabbani SA (2005). Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr Cancer Drug Targets 5, 471-488.
43. Alexandrovich A, Arno M, Patient RK, Shah AM, Pizzey JA, and Brewer AC (2006). Wnt2 is a direct downstream target of GATA6 during early cardiogenesis. Mech Dev 123, 297-311.
44. Katoh M and Katoh M (2007). Conserved POU/OCT- and GATA-binding sites in 5′-flanking promoter region of mammalian WNT8B orthologs. Int J Oncol 30, 1273-1277.
45. Weidenfeld J, Shu W, Zhang L, Millar SE, and Morrisey EE (2002). The WNT7b promoter is regulated by TTF-1, GATA6, and Foxa2 in lung epithelium. J Biol Chem 277, 21061-21070.
46. Zhang Y, Goss AM, Cohen ED, Kadzik R, Lepore JJ, Muthukumaraswamy K, Yang J, DeMayo FJ, Whitsett JA, Parmacek MS, et al. (2008). A Gata6-Wnt pathway required for epithelial stem cell development and airway regeneration. Nat Genet 40, 862-870.
47. de Lau W, Barker N, and Clevers H (2007). WNT signaling in the normal intestine and colorectal cancer. Front Biosci 12, 471-491.
48. Nemer G and Nemer M (2003). Transcriptional activation of BMP-4 and regulation of mammalian organogenesis by GATA-4 and -6. Dev Biol 254, 131-148.
49. Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, and Yang WL (2007). Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 313, 1033-1044.
50. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, Chandler I, Vijayakrishnan J, Sullivan K, Penegar S, et al. (2008). Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 40, 1426-1435.
51. Han X, Boyd PJ, Colgan S, Madri JA, and Haas TL (2003). Transcriptional upregulation of endothelial cell matrix metalloproteinase-2 in response to extracellular cues involves GATA-2. J Biol Chem 278, 47785-47791.
52. Morrisey EE, Musco S, Chen MY, Lu MM, Leiden JM, and Parmacek MS (2000). The gene encoding the mitogen-responsive phosphoprotein Dab2 is differentially regulated by GATA-6 and GATA-4 in the visceral endoderm. J Biol Chem 275, 19949-19954.
53. Setogawa T, Shinozaki-Yabana S, Masuda T, Matsuura K, and Akiyama T (2006). The tumor suppressor LKB1 induces p21 expression in collaboration with LMO4, GATA-6, and Ldb1. Biochem Biophys Res Commun 343, 1186-1190.
54. Caslini C, Capo-Chichi CD, Roland IH, Nicolas E, Yeung AT, and Xu XX (2006). Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 25, 5446-5461.
55. Mano T, Luo Z, Malendowicz SL, Evans T, and Walsh K (1999). Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery. Circ Res 84, 647-654.
56. Fitzgerald K, Bazar L, and Avigan MI (1998). GATA-6 stimulates a cell line-specific activation element in the human lactase promoter. Am J Physiol 274, G314-G324.
57. Shureiqi I, Jiang W, Fischer SM, Xu X, Chen D, Lee JJ, Lotan R, and Lippman SM (2002). GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res 62, 1178-1183.
58. Benasciutti E, Pages G, Kenzior O, Folk W, Blasi F, and Crippa MP (2004). MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 104, 256-262.